Q3 Earnings Estimate for Solid Biosciences Issued By Wedbush

Key Points

• Wedbush analysts have revised their Q3 2025 earnings estimates for Solid Biosciences, projecting a loss of ($0.38) per share, an improvement from their previous estimate of ($0.46).
• Solid Biosciences currently holds an "Outperform" rating from Wedbush, with a target price of $14.00 per share, while the average price target among analysts is $15.00.
• The company's stock performance shows a market cap of $480.46 million, with shares opening at $6.17 and a 1-year trading range between $2.41 and $10.37.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at Wedbush upped their Q3 2025 earnings per share estimates for shares of Solid Biosciences in a research note issued to investors on Wednesday, August 13th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.38) per share for the quarter, up from their prior estimate of ($0.46). Wedbush currently has a "Outperform" rating and a $14.00 target price on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Wedbush also issued estimates for Solid Biosciences' Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.75) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.56) EPS, FY2027 earnings at ($1.58) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at ($0.50) EPS.

A number of other brokerages also recently issued reports on SLDB. JPMorgan Chase & Co. reduced their price target on Solid Biosciences from $15.00 to $13.00 and set an "overweight" rating on the stock in a report on Thursday. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Solid Biosciences in a report on Tuesday, June 17th. Cantor Fitzgerald set a $16.00 target price on Solid Biosciences and gave the stock an "overweight" rating in a report on Monday, July 21st. Piper Sandler reduced their target price on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. Finally, Citigroup assumed coverage on Solid Biosciences in a report on Thursday, June 26th. They set a "buy" rating and a $14.00 target price on the stock. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Solid Biosciences has an average rating of "Buy" and an average price target of $15.00.

Solid Biosciences Price Performance

Shares of NASDAQ:SLDB opened at $6.17 on Friday. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $10.37. The company has a market cap of $480.46 million, a PE ratio of -2.20 and a beta of 2.44. The stock's 50-day moving average is $5.59 and its 200 day moving average is $4.41.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc boosted its position in shares of Solid Biosciences by 208.6% during the second quarter. Legal & General Group Plc now owns 6,011 shares of the company's stock valued at $29,000 after buying an additional 4,063 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock valued at $33,000 after acquiring an additional 4,534 shares in the last quarter. CWM LLC raised its stake in shares of Solid Biosciences by 15,188.5% during the first quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after acquiring an additional 7,898 shares in the last quarter. Corton Capital Inc. bought a new stake in shares of Solid Biosciences during the fourth quarter valued at approximately $41,000. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Solid Biosciences during the second quarter valued at approximately $54,000. Hedge funds and other institutional investors own 81.46% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.